In this work, we demonstrate the effectiveness and long-term durability of the AAV9-Galns gene therapy to treat MPSIVA laying the foundation for future treatment of other diseases with skeletal involvement. This evidence concerns the gene GALNS and mucopolysaccharidosis type 4A.